Johnson & Johnson Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Johnson & Johnson JNJ.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JNJ, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 12 uncommon options trades for Johnson & Johnson.

This isn't normal.

The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.

Out of all of the special options we uncovered, 7 are puts, for a total amount of $657,844, and 5 are calls, for a total amount of $372,121.

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $145.0 to $185.0 for Johnson & Johnson over the last 3 months.

Insights into Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Johnson & Johnson's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Johnson & Johnson's significant trades, within a strike price range of $145.0 to $185.0, over the past month.

Johnson & Johnson 30-Day Option Volume & Interest Snapshot

Biggest Options Spotted:

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Present Market Standing of Johnson & Johnson

• With a trading volume of 1,731,613, the price of JNJ is down by -0.21%, reaching $154.74.
• Current RSI values indicate that the stock is may be approaching overbought.
• Next earnings report is scheduled for 42 days from now.

Professional Analyst Ratings for Johnson & Johnson

In the last month, 5 experts released ratings on this stock with an average target price of $193.8.

• An analyst from UBS has elevated its stance to Buy, setting a new price target at $180.
• An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $178.
• An analyst from RBC Capital persists with their Outperform rating on Johnson & Johnson, maintaining a target price of $181.
• In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215.
• Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Johnson & Johnson with Benzinga Pro for real-time alerts.